41 related articles for article (PubMed ID: 38491392)
1. A-to-I RNA-Editing: An Epigenetic Hallmark Cannot Be Ignored in Silencing the Tumor Microenvironment and Is Promising in Predicting Immunotherapy Response for Esophageal Squamous Cell Carcinoma.
Wang S; Liu C; Zhang C; Xue L; Sun N; He J
Gastroenterology; 2023 Jul; 165(1):275-278.e8. PubMed ID: 36990293
[No Abstract] [Full Text] [Related]
2. Perioperative immunotherapy for esophageal squamous cell carcinoma.
Wei DD; Fang JM; Wang HZ; Chen J; Kong S; Jiang YY; Jiang Y
Front Immunol; 2024; 15():1330785. PubMed ID: 38440724
[TBL] [Abstract][Full Text] [Related]
3. Development of chemotherapeutics for unresectable advanced esophageal cancer.
Imazeki H; Kato K
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1083-1092. PubMed ID: 32820965
[TBL] [Abstract][Full Text] [Related]
4. Proteomic characterization of esophageal squamous cell carcinoma response to immunotherapy reveals potential therapeutic strategy and predictive biomarkers.
Ma F; Li Y; Xiang C; Wang B; Lv J; Wei J; Qin Z; Pu Y; Li K; Teng H; Tan S; Feng J; Shang Z; Wang Y; Tian S; Du C; Han Y; Ding C
J Hematol Oncol; 2024 Mar; 17(1):11. PubMed ID: 38491392
[TBL] [Abstract][Full Text] [Related]
5. PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.
Liu J; Chen H; Qiao G; Zhang JT; Zhang S; Zhu C; Chen Y; Tang J; Li W; Wang S; Tian H; Chen Z; Ma D; Tian J; Wu YL
Cancer Immunol Immunother; 2023 Apr; 72(4):881-893. PubMed ID: 36121452
[TBL] [Abstract][Full Text] [Related]
6. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
[TBL] [Abstract][Full Text] [Related]
7. Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation.
Li H; Miao Y; Zhong L; Feng S; Xu Y; Tang L; Wu C; Zhang X; Gu L; Diao H; Wang H; Wen Z; Yang M
Front Immunol; 2023; 14():1162032. PubMed ID: 37187751
[TBL] [Abstract][Full Text] [Related]
8. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
Ji G; Yang Q; Wang S; Yan X; Ou Q; Gong L; Zhao J; Zhou Y; Tian F; Lei J; Mu X; Wang J; Wang T; Wang X; Sun J; Zhang J; Jia C; Jiang T; Zhao MG; Lu Q
Genome Med; 2024 Apr; 16(1):49. PubMed ID: 38566201
[TBL] [Abstract][Full Text] [Related]
9. A multi-omics study delineates new molecular features and therapeutic targets for esophageal squamous cell carcinoma.
Jin X; Liu L; Wu J; Jin X; Yu G; Jia L; Wang F; Shi M; Lu H; Liu J; Liu D; Yang J; Li H; Ni Y; Luo Q; Jia W; Wang W; Chen WL
Clin Transl Med; 2021 Sep; 11(9):e538. PubMed ID: 34586744
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
Liu J; Yang Y; Liu Z; Fu X; Cai X; Li H; Zhu L; Shen Y; Zhang H; Sun Y; Chen H; Yu B; Zhang R; Shao J; Zhang M; Li Z
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338088
[TBL] [Abstract][Full Text] [Related]
11. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Rizzo A; Ricci AD; Di Federico A; Frega G; Palloni A; Tavolari S; Brandi G
Front Oncol; 2021; 11():803133. PubMed ID: 34976841
[TBL] [Abstract][Full Text] [Related]
12. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.
Chowell D; Yoo SK; Valero C; Pastore A; Krishna C; Lee M; Hoen D; Shi H; Kelly DW; Patel N; Makarov V; Ma X; Vuong L; Sabio EY; Weiss K; Kuo F; Lenz TL; Samstein RM; Riaz N; Adusumilli PS; Balachandran VP; Plitas G; Ari Hakimi A; Abdel-Wahab O; Shoushtari AN; Postow MA; Motzer RJ; Ladanyi M; Zehir A; Berger MF; Gönen M; Morris LGT; Weinhold N; Chan TA
Nat Biotechnol; 2022 Apr; 40(4):499-506. PubMed ID: 34725502
[TBL] [Abstract][Full Text] [Related]
13. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Davis AA; Patel VG
J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
[TBL] [Abstract][Full Text] [Related]
14. iProX: an integrated proteome resource.
Ma J; Chen T; Wu S; Yang C; Bai M; Shu K; Li K; Zhang G; Jin Z; He F; Hermjakob H; Zhu Y
Nucleic Acids Res; 2019 Jan; 47(D1):D1211-D1217. PubMed ID: 30252093
[TBL] [Abstract][Full Text] [Related]
15. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S; Turley SJ; Nickles D; Castiglioni A; Yuen K; Wang Y; Kadel EE; Koeppen H; Astarita JL; Cubas R; Jhunjhunwala S; Banchereau R; Yang Y; Guan Y; Chalouni C; Ziai J; Şenbabaoğlu Y; Santoro S; Sheinson D; Hung J; Giltnane JM; Pierce AA; Mesh K; Lianoglou S; Riegler J; Carano RAD; Eriksson P; Höglund M; Somarriba L; Halligan DL; van der Heijden MS; Loriot Y; Rosenberg JE; Fong L; Mellman I; Chen DS; Green M; Derleth C; Fine GD; Hegde PS; Bourgon R; Powles T
Nature; 2018 Feb; 554(7693):544-548. PubMed ID: 29443960
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
